Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas a...

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) has a valuation score of 60/100 (moderate), profitability score of 0/100 (weak), financial health score of 52/100 (moderate), Piotroski F-Score of 4/9, Altman Z-Score of 0.21 (distressed), revenue growth of +3.8% YoY.

Neutral

Analyst Consensus

Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations21 analysts · 2026-08-01
5
9
7
Strong Buy 5Buy 9Hold 7Sell 0Strong Sell 0
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Valuation & P/E History →Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →